With this in mind, the Society of Surgical Oncology 2016 Choosing Wisely guideline recommended the omission of sentinel node biopsy for T2 or smaller hormone receptor-positive Her2−negative breast cancers in women over 70; this has been widely adopted in many institutions in the United States [6,7]. Here, NR4A1 is linked to breast cancer.